Tim Collard, CEO, Pacific Gene Tech

A Global Animal Health Company

Company OverviewOctober 2016

Pacific GeneTech Limited

C O N F I D E N T I A L


PGT is a commercial stage company applying novel vaccine technologies against multiple diseases Cross-protective vaccines using highly conserved / broad spectrum antigens Orally administrable, eliciting IgA, IgG and T-cell responses Low cost manufacture & vaccine administration Viable alternatives to antibiotics

CompanyFounded in 2009 to commercialize discovery research from leading US Universities Experienced management, top-tier scientific advisors and a global network of R&D collaboratorsOffices in Hong Kong, U.S and Taiwan

ProductsOur technology platforms are covered by 10 patent families- The “Aegis” Recombinant Vaccine Platform- Two Adjuvant / Delivery Systems (“Hercules” & “Javelin”)

Pipeline

Hercules (mannosylated chitosan) is in the market in SE Asia in a novel oral H5N1 vaccine8 vaccine candidates:- 1 registration stage vaccine (Salmonella / Campylobacter for poultry)- 1 pre-registration stage vaccine (Eimeria for poultry)- 2 development stage vaccines (swine Salmonella / E. coli, influenza in poultry & swine)- 4 POC stage (Toxoplasma in mammals, Vibrio & Edwardsiella in fish, Necrotic Enteritis in

poultry, E. coli / EHEC in cows)Javelin (antibody guided antigen adjuvant / delivery system is in the development stage

FocusUnmet or under-served needs in animal health, including food safety & zoonotic diseasese.g. multiple GI Tract Diseases (Bacteria, Parasites) and Influenza

Financials Completed 4 rounds of funding with plans for a public offering in late 2016 / early 2017

Sources: (1) Future Market Insights, Veterinary Vaccines Market, 2016-2026;

2

Introduction to Pacific GeneTech

BY SPECIES

PoultrySwineRuminantsFish

CatsDogs

Our VisionTo Build The World’s Leading Company In 5th Gen Veterinary Vaccines

Current

Future

BY GEOGRAPHY

North America

Asia

Europe

Latin America

Middle East

Africa

Current

Future

BY PRODUCT & TECHNOLOGY

Recombinant

vaccines

Novel Adjuvants

& Delivery Systems

Synthetic

vaccines

Current

Future

PGT uses current, rapid innovation in genetics, molecular biology, immunology and bio-informatics to design cross-protective, low cost vaccines

CROSS-PROTECTION: A MAJOR GAME-CHANGER

3C O N F I D E N T I A L

Both live and killed Aegis vaccines can be administered orally

Oral administration has critical cost benefits with large numbers of animals – e.g. poultry

4

PGT’s Cross-protective, Orally Administrable, Low Cost Vaccines

Salmonella / Campylobacter vaccine is cross-protective against S Typhimurium, Heidelberg, Kentucky, Enteritidis; and E. coli, including a virulent EHEC strain

Eimeria vaccine is cross protective against 5 economically important species of Eimeria; andToxoplasma gondii (a related Apicomplexan parasite)

Cross ProtectionAcross multiple strains and even different species of pathogen

Oral Administration

All PGT’s inactivated Aegis vaccines use the Hercules adjuvant / delivery system Hercules promotes secretory IgA in mucous membranes, preventing pathogen invasion


CONFIDENTIAL

lP Rights

Management

Ind. Knowledge

Investment

PGTDiscovery

Research Universities Research Institutes Companies

Market Channels Out licensees JV/Marketing Partners Direct Sales (B2B)

RevenuesPGT’s revenue streams

License fees, R&D payments, royalties

Direct Sales (Business to Business)

• PGT injects commercial / industry expertise taking discovery ideas through to market

• PGT identifies novel technologies for "first in class” / “best in class” products

In addition to license fee & royalty revenues, PGT generates sales revenues for Hercules

Active PGT Management

Active PGT Management

5

Our Business Model

CONFIDENTIAL

Executive

Chairman

Louis Bowen

• Investment banking, PE/VC industry in Asia since 1970s

• Overseen over 50 investments and acquisitions including companies in the life sciences fields

• Chairman of Asia Capital Management and was a co-founder of the Hong Kong Venture Capital Association

Leadership Team

CEO

Tim Collard

• > 40 years experience in the vaccine, biotechnology and pharmaceutical industries in Asia since the mid-1970s

• Experience MNCs (Squibb, Solvay, Porton) and entrepreneurial companies

• Biology at Bristol University (U.K)

Management Team

Director,

Business

Development

Cindy Tsang

• > 13 years of experience in pharma, investment banking and start-up industries

• Abbott Laboratories, Ernst & Young, Morgan Stanley

• M.B.A from University of Cambridge (U.K), BS Biochemistry from Seattle Univ (U.S)

Director, US

Operations

Dr. Tom

Overbay

• > 25 years of experience in the veterinary pharmaceutical industry

• Founder of Expedite Animal Health

• DVM from the Virginia-Maryland Regional College of Veterinary Medicine

Director,

Translational

Research

Dr. Anna

Obolensky

• > 40 years experience in pharmaceutical industry, research institutions and private equity

• Ph.D in Immunology at Keble College, Oxford

• Fellow of the Royal Society of Medicine/ Member of British Society of Immunology

Director,

R&D

(Taiwan)

Dr. Yahui

Huang

• > 15 years of research experience in academic and industry, regulatory process , technology transfer

• Qualified veterinarian• Ph.D in Biology from

University of Bath (U.K), MS/BS in Veterinary Medicine from National Taiwan Univ.

Director,

Commercial

Projects

Dr. Ariane

Davison

• Experience in the global biotech, healthcare equity and start-up industries

• Ph.D in Viral Immunology from the University of Sydney School of Medicine, and Honors in Molecular Genetics.

Scientific Advisors

Scientific

Advisor (US)

Dr. Billy Hargis

• Leads the University’s vaccine research team

• Research Director of the Poultry Health Laboratory (PHL) at the University of Arkansas

• D.V.M and Ph.D. training at the Univ of Minnesota

Scientific

Advisor (US)

Dr. Lisa Bielke

• Assistant Professor, Department of Animal Sciences, OARDC, Ohio State University

• Ph.D in Poultry Science at the University of Arkansas

• Board of Trustees for the Poultry Science Association Foundation

Our Leadership & Management Structure

6

Scientific

Advisor

Dr. Steve Chu

• > 30 years of experience in veterinary vaccine R&D

• Senior research positons with Ceva, Elanco, Fort Dodge.

• Ph.D in Microbiology from UC Davis, MS/DVM from National Taiwan Univ.

TaiwanGuangzhou

AustraliaNew Zealand

Indonesia

Thailand

Oxford

Edinburgh

Rhode Island

Ontario

GeorgiaTexasArkansas

Ohio

CONFIDENTIAL7

U of Arkansas

Lead-inventor, Aegis, Hercules.

Salmonella, Campy, Eimeria,

Avian Influenza research (poultry)

Texas A&M

Co-inventor of Aegis, Javelin.

Javelin development

Guelph U, Ontario

Co-inventor of Aegis, Eimeria

research (poultry)

Kansas State U, KS

E coli / EHEC (in-vitro model)

Vaccines Adjuvant / Delivery Systems

Pingtung U, Taiwan

E coli, Toxoplasma (mouse

model), Salmonella (pigs),

Vibrio & Edwardsiella (fish)

Chung Hsing U, Taiwan

Eimeria (poultry)

Zhong Shan U, China

Fish vaccine research

Medion, Indonesia

Avian Influenza

AFRIMS (Walter Reed),

Thailand

E coli & Salmonella

(mouse model)

Gamma Vaccines,

Australia

RBC, New Zealand

Toxoplasma & Neospora

(sheep)

Oxford

Hercules mode of

action research

Edinburgh U

Moredun / Roslin Inst.

E coli / EHEC (cows)

USDA, GA

Avian Influenza

research (poultry)

Epivax, RI

Toxoplasma mode of

action research

Ohio State UCo-inventor of Aegis.

Eimeria & Necrotic

Enteritis research

(poultry)

N America

Europe Asia/PacificA

Taiwan/China

V

V

V

A

A

A

A

A

V

V

V

V

V

A

A

A

V

V

V

Stirling U

Fish vaccine research

V

Kansas

A Growing Global Network of R&D Collaborators

Provisional Application

US Utility Application

PCT National Filings

Vaccines

1. Universal flu epitopes + CD154 (I.E.)

2. Eimeria TRAP epitope

3. fliC epitope for Enterobacteriaceae

4. Bacillus vectored HMGB1 (I.E.)

5. Campylobacter epitope + I.E. domains

6. PAL epitope for Enterobacteriaceae In process

7. Eimeria MPP epitope In process

8. Yeast Vector In process

Adjuvant / Delivery Systems

9. Hercules Modified Chitosan Adjuvant (MCA) In process

10. Javelin Antibody-guided Antigen (AgA)

8 Aegis Vaccine Patents filed globally + 2 Adjuvant / Delivery System Patents

Many of the above patents have been issued in multiple territoriesC O N F I D E N T I A L

PGT’s Patent Status

8

Salmonella +Campylobacter

Eimeria

Influenza

Salmonella & E. coli

Influenza

E coli (ETEC / EHEC)

ToxoplasmaCryptosporidium

Neospora

EdwardsiellaVibrio

Toxoplasma

Cross-protection Creates Synergies: Same Antigen Packages, Multiple Diseases

Poultry Swine Ruminants Fish Others


3 vaccine families with broad cross-protection across multiple pathogen families in multiple animals

Red: GIT Bacteria Blue: Parasites Green: Viruses

9

Our Existing Aegis Vaccine Candidates


Adjuvants / Delivery Systems

PGT Hercules (modified chitosan)

AvianInfluenza and

others

PGT Javelin (vaccine delivery system)

Avianinfluenza

Animal Vaccine Program

Food Safety/Enteric DiseaseSalmonella & Campylobacter

avian

Eimeriaavian

Food Safety/Enteric Disease (E. coli/EHEC)

ruminant

Food Safety/Enteric DiseaseSalmonella & E. coli

swine

Avian Influenza avian

Toxoplasmosisfeline &

ruminants

Necrotic Enteritis avian

Edwardsiella/Vibrosis fish

Launched in Q3 2016 in an oral H5N1 vaccine

Anticipated launch in 2017

USDA SIF filing Q2 2016; anticipate launch in 2018

Out-licensing opportunity for S. Amer. in Q4 2016 and N. Amer. in Q1 2017; US regulatory filing in 2017; Anticipated first launch in 2019

Discovery Research

Proof of Concept

DevelopmentRegulatory

ProcessMarket

Seeking partners & out-licensing opportunities

POC animal studies in progress



10

Our Pipeline Status – Multiple Value Drivers

POC animal studies in progress


Aegis: A Breakthrough, Potentially Disruptive Recombinant Vaccine Platform

COOHNH2

Vector Cell Membrane

Inside of the cell

Conserved Epitope (Antigen)

Immune Potentiator e.g., HMGB1, CD40L

• Conserved antigens alone = poor protection

• Conserved antigens + immuno-potentiators = solid protection

11

PGT’s Patented Vaccine Technologies: Aegis, Hercules & Javelin

Hercules:

Mannosylated Chitosan adjuvant / delivery system is “sticky” – it passively adheres to mucous membranes and Antigen Presenting Cells in mucous membranes

Javelin:

Is guided to target by an antibody and actively adheres to CD40 on APCs

PGT is a commercial stage animal health biotech focused on:

Novel / breakthrough vaccine technologies

Unmet or under-served needs

Zoonotic diseases

Seeks partners for:

Out-licensing our vaccine technologies to suitable MNC and national-level commercial partners

In-licensing additional novel vaccine technologies

Research Collaborations

PGT has an attractive business model and is well positioned for an IPO:

We are planning a public offering in Taiwan; and

Raising a pre-IPO funding round

CONFIDENTIAL12

Investment Summary

CONFIDENTIAL

Appendix 1: How the Technology Works

14

• Developed using recombinant genetics• Platform incorporates combinations of key immuno-potentiating molecules e.g., CD40L, HMGB1

• Cloned with antigen sequences highly conserved between pathogens e.g., Salmonella, E.coli, Influenza

• The immuno-potentiators stimulate inflammatory cascades/cells and trigger immune responses• The vaccine construct specifically stimulates pathogen-specific immune responses

CONFIDENTIAL

A Breakthrough/Disruptive Recombinant Vaccine Platform:

COOHNH2

Vector Cell Membrane

Loop 1 9

2

Inside of the cell

Conserved Epitope (Antigen)

Immune Potentiator e.g., CD40L (multiple copies)

References: 1. Foodborne Path. and Disease, 2014, 11(2):165-169. 2. Int. J. Biotech. and Bioeng. Res. 2013, 4(6):589-596. 3. Clin. Vaccine Immunol., 2011, 18(3) 449-454. 4. Int. J. Poultry Science 2010, 9(11):1031-0137. 5. Poultry Science, 2010, 89:1399–1405. 6. Poultry Science, 2009, 88:2244–2252.

The Patented Aegis Vaccine TechnologyImmune Potentiation + Conserved Antigens

CONFIDENTIAL

HMGB1 is a highly conservedubiquitous protein, present in bothcellular nuclei and cytoplasm.

• Secreted by key immune cellse.g., macrophages and dendritic cells,in response to infection and damage.

• Binds and signals through TLR4 andRAGE, producing cytokines,e.g. TNF, IL-1α/β, inducing signalingcascades that mediate inflammationand innate immunity.

• Proposed as a potential vaccineadjuvant, capable of enhancingadaptive effector and memoryimmune responses. 1

Source: 1. Nature Reviews Immunology 5, 331-342 (2005)

Scientific Basis for Immune Potentiation with HMGB1

15

CONFIDENTIAL

CD40L (CD154) is expressed on activatedT cells and is a member of the TNFsuperfamily.

CD40 is expressed by B cells, macrophages,dendritic cells, monocytes, mast cells,fibroblasts, and endothelial cells.

CD40/CD40L-mediated signals activate antigenpresenting cells, induce and regulate thegeneration of T cell-dependent and humoralimmune responses.

Cognate B-cell/T-cell interactions are critical forsuccessful immunization, resulting in enhancedimmune responses, pro-inflammatory cytokineexpression, immunoglobulin class switching,(e.g., from IgG to IgA) and the induction ofimmunological memory. Source: Nature Immunology 8, 391-397 (2008)

Scientific Basis for Immune Potentiation with CD40L

16

Mannosylated Chitosan:• Binds to both antigens, and mannose receptors (CD206) on the surface of Antigen

Presenting Cells (APCs) - naturally adjuvates responses• Particularly important in inducing mucosal / IgA secretory immunity

Hercules is a universal carrier delivering selected antigens to the Antigen Presenting Cells of the immune system

Antigen

MannosylatedChitosan

APC (Dendritic Cell / Macrophages)


Hercules is “sticky” – it passively adheres to mucous membranes and Antigen Presenting Cells in the mucous membranes

The Hercules Adjuvant / Delivery System Technology

17

Javelin is designed to induce fast, robust + long-lived specific IgG and IgA responses

CD40 is expressed on antigen presenting cells (APCs) and is required for true activation. Induces innate (TNF) expression and binds T&B cells – expansion and replication Administration of specific antigens with CD40 targets APCs in the mucosa-associated

lymphoid tissue (MALT) and enhances systemic specific IgG + IgA(s) responses


Javelin is guided to target by an antibody – it actively adheres to CD40 on Antigen Presenting Cells

APC + CD40

CD40 antibody

Antibody

Antigen

Javelin complex binds antibody to CD40 on APC and antibody to vaccine antigen (e.g. influenza virus)

The Javelin Adjuvant / Delivery System Technology

18

CONFIDENTIAL

Appendix 2: Data Summaries

CONFIDENTIAL 20

Food Safety/Enteric Disease Vaccine

• A significant public health concern worldwide

• Human salmonellosis associated with the consumption of contaminated foods, such as fresh and processed meat and poultry, eggs, and fresh produce.

• According to USDA ERS, foodborne illness costs the US economy US$6.9 billion a year, of which Salmonella costs US$3.7 billion, E. coli O157 at US$478 million and Campylobacter at US$1.9 billion

Trial Achievements

PGT Salmonella vaccine demonstrated significant reduction after challenge with Salmonella Typhimurium.

PGT Salmonella vaccine demonstrated cross-protection against S Typhimurium, Heidelberg, Kentucky, Enteritidis(the most common food-borne illness serotypes of Salmonella)

Salmonella vaccine is also cross-protective against E. coli

PGT Technology• Different vectors of choice: Bacillus, Salmonella

(inactivated and live)• Expresses PAL, CJ0113, HMBGI as a fusion protein on the

surface cell vector• CJ0113 is a Campylobacter antigen and our ultimate aim

to market a combined broad spectrum Salmonella and Campylobacter vaccine for the food safety market

C O N F I D E N T I A L 21

Effect of live vaccination with the PGT Aegis vaccine on Salmonella Enteritidis recovery from ceca 10 days post challenge

PGT Aegis vaccine (live) against Salmonella Enteritidis

PGT Aegis vaccine (killed) against Salmonella Heidelberg

Effect of vaccination with killed PGT Aegis vaccine on Salmonella Heidelberg recovery from ceca 10 days post challenge

PGT live and killed vaccines demonstrate significant cross-protection across different Salmonella strains

Analysis of Vaccine Protection against E. coli with Hercules adjuvated recombinant killed vaccine (AFRIMS, Thailand)

0

10

20

30

40

50

60

70

80

90

100

Ileum Colon Cecum

Per

cen

t re

cove

ry E

TEC

Control

1 dose

2 doses

*P<0.05

*Significantly different (P<0.05) than Control

Cross-protection in E. coliHercules-adjuvated PGT oral Salmonella vaccine is protective in mice against E. coli

C O N F I D E N T I A L22

CONFIDENTIAL 23

Eimeria Vaccine

• Coccidiosis is a common disease caused by Eimeria parasites occurring in the digestive tract of poultry.

• Worldwide poultry losses due to coccidiosis are estimated to be between US$750 million and more than US$1.5 billion per year.

• Coccidiosis vaccines are among the most expensive vaccines in poultry production. No innovations in this market have occurred since the introduction of live oocyst vaccines in the 1960s.

• Current LIVE Eimeria vaccines are difficult to use and not popular with farmers

Trial Achievements

PGT Eimeria vaccine demonstrated cross protection against 5 economically important species of this parasite

PGT Eimeria vaccine radically reduced mortality post Eimeria maxima challenge

PGT Eimeria vaccine provided higher Body Weight (BW) and Body Weight Gain (BWG) of chicks post Eimeriamaxima challenge

PGT Technology• Orally administered bacillus vectored inactivated stand

alone vaccine in development• Expresses MPP, TRAP, HMBGI as a fusion protein on the

vector surface• The successful introduction of novel and effective PGT

vaccines against coccidiosis and necrotic enteritis will be a major advance for the poultry industry and the first such event in Eimeria and Clostridium perfringens control in decades

The Study

Vectored vaccines MPP HMGB1 and

TRAP MPP HMGB1 were tested for

ability to provide protection against

an Eimeria maxima challenge when

administered through the drinking

water in conjunction with a modified

chitosan adjuvant.

Broiler chicks were vaccinated at 4

and 14 days of age with the

respective vaccine in the drinking

water and challenged at day 21.



A B

PGT oral Eimeria vaccine candidates A + B adjuvated with Hercules radically reduce mortality by Eimeria maxima

24

CONFIDENTIAL

Vaccine Challenge

Strain Vaccine dose

Primary site

for lesion

scores

Oocyst Vaccine + PGT

Recombinant Vaccine

Oocysts w/o

PGT Vac

Oocysts +

PGT Vac

Live Oocyte

Vaccine

E. brunetti 40Large

Intestine Failed Passed

E. maxima 10Jejunum &

Ileum Failed Passed

E. necatrix 50 Jejunum Failed Passed

E. acervulina 150 Duodenum Passed Passed

E. tenella 25 Cecum Passed Passed

• 5 treatment groups, a vaccinated group (Group 1), a vaccinated group in combination with a low level of PGT’s Eimeria vaccine (Group 2), another vaccinated group in combination with a high level of PGT vaccine (Group 3), an unvaccinated positive control group (Group 4), and an unvaccinated unchallenged negative control group (Group 5).

• Groups 1 through 4 were challenged at 22 days of age and necropsied at 27 through 29 days of age. The primary response variable for establishing minimum protective dose was post-challenge intestinal lesion scores in the duodenum, jejunum, ileum, ceca, or large intestine depending on the primary replication site of each Eimeria species.

PGT’s Eimeria vaccine is cross-protective against 5 major species of Eimeria

Eimeria Vaccine: Cross-protection

25

CONFIDENTIAL 26

Toxoplasma gondii Vaccine

• Toxoplasma gondii, an economically important Apicomplexan parasite, causes abortion in sheep and presents a threat to humans, particularly pregnant women.

• Most mammals including humans can become infected with T. gondii (est. 23% in the US). Toxoplasmosis can develop in 'high risk' groups of individuals whose immunity is impaired, Congenital infection occurs in about 400-4,000 babies each year (result in retinal scars in both eyes, and permanent vision damage or blindness).

• Cats are the only mammal in which it reproduces, multiplies, and is shed back into the environment.

• No vaccine for cats currently on the market.

Trial Achievements

PGT Eimeria vaccine demonstrated cross protection against a similar parasite, T. gondii

Provided 80% protection after challenge in a pilot/proof of concept study

PGT Technology

• Orally administered bacillus vectored inactivated Eimeria stand alone vaccine

0

2

4

6

8

10

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28

CULMULATIVE MORTALITY

Group 1 Group 2 Group 3 Group 4 Group 5

G 5 (unvaccinated, unchallenged) no mortality.

G 4 (no vaccine, challenged) 100% mortality.

G 1 (oral high dose) 50% survival.

G 2 (oral low dose) and G 3 (peritoneal injection) 80% survival, significantly higher (P<0.05) than G 4.

C O N F I D E N T I A L 27

Cross-protection of Eimeria vaccine against Toxoplasma gondiiPGT killed Eimeria vaccine adjuvated with Hercules radically reduces mortality by T. gondii

Significant Results to Date

1. Superior immune response compared with

other adjuvants with minimal injection site

reaction.

Parenteral study of Hercules + inactivated

vaccine

2. Significant immune response observed via

oral administration including in drinking

water in animal studies with Hercules +

inactivated vaccines.

Key significance of oral administration:

parenteral injection is very labor intensive

to animals , esp. poultry

3. Successful POC challenge studies

conducted with Hercules + inactive

vectors.

Study conducted with MNC licensee

Hercules AdjuvantSignificant Results and Opportunities of Interest

Veterinary Markets of Interest *

Farm Animals

Aquaculture

Companion Animals

• Not in order of priority• Markets where Hercules has been tested or

currently being tested in various vaccines


* = p < 0.05

0

10

20

30

40

50

60

70

80

90

100

Control Chitosan Chitosan + CTB Chitosan +Saponin

MannosylatedChitosan

Pe

rce

nt

Re

cove

ry o

f Sa

lmo

ne

lla

Liver/Spleen

* *

*

Salmonella Recovery Liver/Spleen (L/S) or Cecal Tonsil (CT) on Day 22

(3 days following challenge)

*

S. Enteritidis challenge

on d19

S. Enteritidis recovery

on d22

• Serum IgG

• GIT mucosal IgA

The Study

Addition of Hercules yields zero percent recovery of Salmonella in the liver/spleen and

the lowest percent recovery in the cecal tonsil when compared with other adjuvants.

Comparison of Salmonella recovery following challenge with various adjuvants


Immune response to vaccination against swine influenza virus (iSIV)

The Study

One week after challenge, the IM/Oral/X combination resulted in the highest HI titers.

0

10

20

30

40

50

60

70

Bleed 1 Bleed 2 Bleed 3 Bleed 4 Bleed 5 (7 days postchallenge)

IM-ORAL-X

IM-X-ORAL

X-X-ORAL

No vaccine-CONTROLS

3 dose combinations: X = no vaccination

HI T

iter

Challenge isolate Heterologous H1N1Combinations of vaccination at weaning, 2 weeks post wean and 4 weeks post wean

Vaccinated -IM Vaccinated - ORAL Challenged with Heterologous Flu 1 wk post challenge

Bleed 1 (at weaning) Bleed 2 (2wks post wean) Bleed 3 (4wks post wean) Bleed 4 (6wks post wean) Bleed 5 (1wk post challenge)

Combinations of vaccination for an oral H1N1 vaccine and Hercules against swine flu in pigs


0

10

20

30

40

50

60

70

80

90

100

Ileum Colon Cecum

Per

cen

t re

cove

ry E

TEC

Oral ETEC Challenge without Hercules

Control

1 dose

2 doses

Killed Bacillus-vectored Salmonella Aegis vaccine against ETEC E. coli in a Mouse Model (AFRIMS)

Analysis of 2 dose Aegis Vaccine Protection against ETEC with

Hercules adjuvated and non-adjuvated recombinant killed vaccine

0

20

40

60

80

100

Ileum Colon CecumP

erce

nt

reco

very

ETE

C

Oral ETEC Challenge with Hercules

Control

1 dose

2 doses

**

*P<0.05

*

There is a clear demonstration that the Hercules-adjuvated (vs the non-adjuvated) PGT construct has an

immuno-protective effect in mice against ETEC challenge as evidenced by statistically significant

reduction of ETEC in the gut after an oral challenge.


CONFIDENTIAL31

CONFIDENTIAL

1. Vaccination of chickens with recombinant Salmonella-expressing M2e and CD154 epitopes increases protection and decreases viral shedding after low pathogenic avian influenza challenge. 2009, Poultry Science, 88 : 2244 – 2252

2. Evaluation of recombinant Salmonella expressing CD154 for persistence and enhanced antibody response in commercial turkeys. 2010, Poultry Science, 89 : 1399 – 1405

3. Development and evaluation of an ΔaroA / ΔhtrA Salmonella Enteritidis vector expressing Eimeria maxima TRAP family protein Em TFP250 with CD154 (CD40L) as candidate vaccines against coccidiosis in broilers. International Journal of Poultry Science, 9(11) : 1031-1037, 2010

4. Evaluation of Salmonella peptide epitopes for reduction of C. jejuni in broiler chickens. Clinical and Vaccine Immunology, March 2011, p449 – 454

1. Scarless and site-directed mutagenesis in Salmonella Enteritidis chromosome. BMC Biotechnology, 2007, 7 : 59

Key PGT Publications

32

Pacific GeneTech Limited17/F China Hong Kong Tower

8-12 Hennessy RoadHong Kong

Tel: +852-2525-8151web: www.pacificgenetech.com

contact: [email protected]

Contact Us

CONFIDENTIAL

Tim Collard, CEO, Pacific Gene Tech

Business

Transcript of Tim Collard, CEO, Pacific Gene Tech